Is Neurocrine Biosciences (NBIX) Still Undervalued Or Does Its P E Leave Little Upside?
Neurocrine Biosciences (NBIX) stock remains in focus after recent trading saw mixed short term moves, with the share price declining 0.4% over the past day but increasing over the past month and the past 3 months.
See our latest analysis for Neurocrine Biosciences.
Looking beyond the latest pullback, Neurocrine Biosciences has a 30 day share price return of 7.47% and a 90 day share price return of 28.24%, while the 1 year total shareholder return of 29.43% and 3 year total shareholder return of 72.97% point to momentum that long term holders will compare against the current share price of $170.88.
If you are considering other opportunities in healthcare and related technologies, this is a good moment to scan the market using the 39 healthcare AI stocks.
After that strong run and a current price of $170.88, Neurocrine Biosciences now poses a straightforward question: does the balance of risk and potential reward still lean toward buyers as the valuation work begins?
Most Popular Narrative: 11.4% Undervalued
Against the last close of $170.88, the most followed narrative points to a fair value of $192.88, framing Neurocrine Biosciences as modestly undervalued based on forecast cash flows and earnings power discounted at 7.11%.
A broad, late-stage and diversified CNS pipeline, including multiple Phase III programs targeting major depressive disorder and schizophrenia, leverages advances in precision medicine and increases visibility for future earnings, supporting potential future valuation multiple expansion.
Ongoing internal innovation in biologics (such as bispecifics, ADCs, peptides), and a strong preclinical pipeline, allows Neurocrine to capitalize on industry advancements in drug modalities, expanding the addressable market and supporting long-term revenue growth.
Want to understand why this narrative still arrives at a higher fair value than today’s share price? The story leans heavily on faster profit growth, richer margins over time, and a future earnings multiple that assumes investors keep paying up for Neurocrine Biosciences if those targets are met.
Result: Fair Value of $192.88 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the picture for Neurocrine Biosciences is not risk free, with INGREZZA pricing pressure and potential Crenessity uptake limits both capable of challenging this upbeat narrative.
Find out about the key risks to this Neurocrine Biosciences narrative.
Another View: What Multiples Say About Neurocrine Biosciences
While the SWS DCF model frames Neurocrine Biosciences as deeply undervalued, the simple P/E check tells a cooler story. At 25.7x earnings, the stock trades above both the US Biotechs industry at 17.3x and peers at 23.4x, and only slightly below its fair ratio of 26x, raising the question of how much valuation cushion is really left.
For a closer look at how that earnings multiple stacks up against the fair ratio and peers, and what it could mean for valuation risk or opportunity, See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If this mix of optimism and caution around Neurocrine Biosciences resonates, do not wait to check the figures for yourself and weigh both sides using 3 key rewards
Looking for more investment ideas beyond Neurocrine Biosciences?
If Neurocrine Biosciences has sharpened your focus, use this momentum to broaden your watchlist and test fresh ideas before the next wave of opportunities emerges.
- Spot potential mispricings early by scanning 47 high quality undervalued stocks that pair solid fundamentals with room for sentiment to catch up.
- Strengthen your core holdings by reviewing the solid balance sheet and fundamentals stocks screener (47 results) that can help anchor a portfolio when conditions get tougher.
- Stay a step ahead of the crowd by checking the screener containing 20 high quality undiscovered gems that many investors may not be watching yet.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com